Chemomab Therapeutics
CMMB
8 hedge funds and large institutions have $3.11M invested in Chemomab Therapeutics in 2019 Q1 according to their latest regulatory filings, with 8 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.02% more ownership
Funds ownership: 0% → 0.02% (+0.02%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$1.58M |
| 2 |
AIC
AWM Investment Company
New York
|
+$790K |
| 3 |
RI
RTW Investments
New York
|
+$477K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$340K |
| 5 |
DG
Delek Group
Herzliya,
Israel
|
+$206K |
Top Sellers
CMMB Hedge Fund Activity: Q1 2019 in Review
8 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Chemomab Therapeutics (CMMB) for Q1 2019, worth a combined $3.11M.
Buyers outnumbered sellers: 8 funds opened new CMMB positions and 0 closed out — a net gain of 8 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Kennedy Capital Management, opening a new position worth an estimated $1.58M.
- 8 institutional investors held Chemomab Therapeutics (CMMB) as of Q1 2019, up from 0 in Q4 2018.
- Funds reported $3.11M of Chemomab Therapeutics stock for Q1 2019.
- 8 funds opened new Chemomab Therapeutics positions in Q1 2019 and 0 closed out, a net change of +8 holders.
- The largest Chemomab Therapeutics buyer in Q1 2019 was Kennedy Capital Management, an estimated $1.58M added.
Based on aggregated 13F filings for Q1 2019.